Name: | Clodronate |
---|---|
Name (isomeric): | DB00720 |
Drug Type: | small molecule |
Brand: | Acide Clodronique [INN-French], Dichloromethanediphosphonic acid, Bonefos, Clasteon, Loron, Acidum Clodronicum [INN-Latin], Ostac, Dichloromethylidene diphosphonate, Acido Clodronico [INN-Spanish] |
Category: | Antihypocalcemic Agents, Osteoporosis Prophylactic, Bisphosphonates, Antineoplastic Agents, Bone Density Conservation Agents |
CAS number: | 10596-23-3 |
Indication: | For the management of hypercalcemia of malignancy and as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors. |
---|---|
Pharmacology: |
Clodronate is a first generation (non-nitrogenous) bisphosphonate in the same family as etidronate and tiludronate. Clodronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the clodronate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the ki...
show more » |
Mechanism of Action: |
The bisphosphonate group binds strongly to the bone mineral, hydroxyapatite. This explains the specific pharmacological action of these compounds on mineralized tissues, especially bone. The exact mechanism of action of clodronate is not known, however it is known that it does not inhibit protein isoprenylation but can be metabolized intracellularl...
show more » |
Absorption: | After oral administration, absorption is estimated at 1–3% of the ingested dose because of the low uptake from the gastrointestinal tract. |
Protein binding: | 2%-36% |
Biotransformation: | Clodronate is not metabolized in humans. |
Half Life: | Approximately 13 hours. |
Toxicity: | Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients. |
Affected organisms: | Humans and other mammals |
Food interaction: |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug interaction: |
|